Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| COLLEGIUM PHARMACEUTICAL, INCCOLL · Entity 5169 | EVP & Chief Commercial Officer | March 03, 2026 | March 05, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
COLLEGIUM PHARMACEUTICAL, INC
Report date March 03, 2026 · Filed March 05, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 71,770 |
Ending reported balance
After 2026-03-03 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-03-03 · Sale · Disposed 46,417 · Balance 75,329 F1: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 3, 2025. F2: The price reported in column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $39.835 to $40.82, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) and (3) to this Form 4. Row 2 · 2026-03-03 · Sale · Disposed 3,559 · Balance 71,770 F1: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 3, 2025. F3: The price reported in column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $40.84 to $41.35, inclusive. |
Filing footnotes · ownership attribution and instrument terms
F1: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 3, 2025.
F2: The price reported in column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $39.835 to $40.82, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) and (3) to this Form 4.
F3: The price reported in column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $40.84 to $41.35, inclusive.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 10, 2022 Filed Feb 14, 2022 23:36 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | Tax withholdingCommon Stock | 4,016 | $17.63 | $70,802.08 |
DisclosureSEC source: 0001062993-22-004318 · form4.xml · nonDerivative · entry 4 Dreyer Scott · CIK 0001746251 · EVP & Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 131,785 F4 · shares: Shares withheld by the issuer to satisfy applicable withholding taxes upon vesting of performance stock units. Read SEC document |
| February 10, 2022 Filed Feb 14, 2022 23:36 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | Tax withholdingCommon Stock | 6,643 | $17.63 | $117,116.09 |
DisclosureSEC source: 0001062993-22-004318 · form4.xml · nonDerivative · entry 3 Dreyer Scott · CIK 0001746251 · EVP & Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 135,801 F3 · shares: Shares withheld by the issuer to satisfy applicable withholding taxes upon vesting of restricted stock units. Read SEC document |
| February 10, 2022 Filed Feb 14, 2022 23:36 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | GrantCommon Stock | 13,675 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001062993-22-004318 · form4.xml · nonDerivative · entry 2 Dreyer Scott · CIK 0001746251 · EVP & Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 142,444 F2 · price: On February 10, 2022, the Compensation Committee of the Board of Directors of the issuer determined that performance-vesting criteria were met with regard to an aggregate of 13,675 performance share units granted in the issuer's three prior fiscal years. Read SEC document |
| February 10, 2022 Filed Feb 14, 2022 23:36 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | GrantCommon Stock | 52,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-22-004318 · form4.xml · nonDerivative · entry 1 Dreyer Scott · CIK 0001746251 · EVP & Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 128,769 F1 · shares: Reflects the grant of restricted stock units. Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. Twenty-five percent (25%) of the restricted stock units vest on February 10, 2023, and the balance of the restricted stock units vest in equal annual installments over the following three-year period, subject to the reporting person's continued service with the issuer. The restricted stock units will be settled on each applicable vesting date in shares of the issuer's common stock. Read SEC document |
| January 10, 2022 Filed Jan 12, 2022 21:22 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | Tax withholdingCommon Stock | 701 | $19.05 | $13,354.05 |
DisclosureSEC source: 0001879789-22-000002 · primary_doc.xml · nonDerivative · entry 1 Dreyer Scott · CIK 0001746251 · EVP & Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 76,269 F1 · shares: Shares withheld by the Issuer to satisfy applicable withholding taxes upon vesting of restricted stock units. Read SEC document |
| December 15, 2021 Filed Dec 17, 2021 21:33 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | SaleCommon Stock | 5,693 | $18.33 | $104,352.69 |
DisclosureSEC source: 0001879789-21-000022 · primary_doc.xml · nonDerivative · entry 1 Dreyer Scott · CIK 0001746251 · EVP & Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 76,970 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 14, 2021 and amended on September 1, 2021. F2 · price: The price reported in column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $17.95 to $18.62, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2). Read SEC document |
| July 12, 2021 Filed Jul 14, 2021 20:17 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | Tax withholdingCommon Stock | 595 | $23.17 | $13,786.15 |
DisclosureSEC source: 0001104659-21-092117 · tm2122232-1_4seq1.xml · nonDerivative · entry 1 Dreyer Scott · CIK 0001746251 · EVP & Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 82,663 F1 · shares: Shares withheld by the Issuer to satisfy applicable withholding taxes upon vesting of restricted stock units. Read SEC document |
| February 11, 2021 Filed Feb 12, 2021 21:16 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | SaleCommon Stock | 5,798 | $25.33 | $146,863.34 |
DisclosureSEC source: 0001192482-21-000151 · edgar.xml · nonDerivative · entry 4 Dreyer Scott · CIK 0001746251 · EVP & Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 83,258 F3 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 19, 2020 F5 · price: The price reported in column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $25.01 to $25.95, inclusive. Read SEC document |
| February 11, 2021 Filed Feb 12, 2021 21:16 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | SaleCommon Stock | 2,100 | $24.89 | $52,269.00 |
DisclosureSEC source: 0001192482-21-000151 · edgar.xml · nonDerivative · entry 3 Dreyer Scott · CIK 0001746251 · EVP & Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 89,056 F3 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 19, 2020 F4 · price: The price reported in column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $24.66 to $25.00, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (4) and (5). Read SEC document |
| February 10, 2021 Filed Feb 12, 2021 21:16 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | Tax withholdingCommon Stock | 3,283 | $25.95 | $85,193.85 |
DisclosureSEC source: 0001192482-21-000151 · edgar.xml · nonDerivative · entry 2 Dreyer Scott · CIK 0001746251 · EVP & Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 91,156 F2 · shares: Shares withheld by the Issuer to satisfy applicable withholding taxes upon vesting of restricted stock units. Read SEC document |
| February 10, 2021 Filed Feb 12, 2021 21:16 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | Tax withholdingCommon Stock | 1,901 | $25.95 | $49,330.95 |
DisclosureSEC source: 0001192482-21-000151 · edgar.xml · nonDerivative · entry 1 Dreyer Scott · CIK 0001746251 · EVP & Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 94,439 F1 · shares: Shares withheld by the Issuer to satisfy applicable withholding taxes upon vesting of performance stock units. Read SEC document |
| January 19, 2021 Filed Jan 21, 2021 21:31 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | GrantStock Option (Right to Purchase) · Derivative | 130,800 | $0.00 Strike: $24.06 | $0.00 |
DisclosureSEC source: 0001192482-21-000087 · edgar.xml · derivative · entry 3 Dreyer Scott · CIK 0001746251 · EVP & Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 130,800 Underlying: Common Stock · 130,800 shares Expires 2031-01-19 F3 · derivative.exercise_date: Twenty-five percent (25%) of the option vests and becomes exercisable on February 10, 2022, and the balance vests in equal quarterly installments (rounded up to the nearest whole share of common stock) over the following three-year period, subject to the reporting person's continued service with the issuer. Read SEC document |
| January 19, 2021 Filed Jan 21, 2021 21:31 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | GrantCommon Stock | 6,165 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001192482-21-000087 · edgar.xml · nonDerivative · entry 2 Dreyer Scott · CIK 0001746251 · EVP & Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 96,340 F2 · price: On January 19, 2021, the Compensation Committee of the Board of Directors of the issuer determined that performance-vesting criteria were met with regard to 6,165 performance share units granted in two prior years. Read SEC document |
| January 19, 2021 Filed Jan 21, 2021 21:31 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | GrantCommon Stock | 45,780 | $0.00 | $0.00 |
DisclosureSEC source: 0001192482-21-000087 · edgar.xml · nonDerivative · entry 1 Dreyer Scott · CIK 0001746251 · EVP & Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,175 F1 · shares: Reflects the grant of restricted stock units. Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. Twenty-five percent (25%) of the restricted stock units vest on February 10, 2022, and the balance of the restricted stock units vest in equal annual installments over the following three-year period, subject to the reporting person's continued service with the issuer. The restricted stock units will be settled on each applicable vesting date in shares of the issuer's common stock. Read SEC document |
| January 19, 2021 Filed Jan 22, 2021 21:10 UTC Amendment | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | GrantCommon Stock | 6,165 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001192482-21-000098 · edgar.xml · nonDerivative · entry 2 Dreyer Scott · CIK 0001746251 · EVP & Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 96,340 F2 · price: On January 19, 2021, the Compensation Committee of the Board of Directors of the issuer determined that performance-vesting criteria were met with regard to 6,165 performance share units granted in two prior years. Read SEC document |
| January 19, 2021 Filed Jan 22, 2021 21:10 UTC Amendment | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | GrantCommon Stock | 45,780 | $0.00 | $0.00 |
DisclosureSEC source: 0001192482-21-000098 · edgar.xml · nonDerivative · entry 1 Dreyer Scott · CIK 0001746251 · EVP & Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,175 F1 · shares: Reflects the grant of restricted stock units. Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. Twenty-five percent (25%) of the restricted stock units vest on February 10, 2022, and the balance of the restricted stock units vest in equal annual installments over the following three-year period, subject to the reporting person's continued service with the issuer. The restricted stock units will be settled on each applicable vesting date in shares of the issuer's common stock. Read SEC document |
| January 15, 2021 Filed Jan 20, 2021 21:15 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | SaleCommon Stock | 1,322 | $22.89 | $30,260.58 |
DisclosureSEC source: 0001192482-21-000063 · edgar.xml · nonDerivative · entry 1 Dreyer Scott · CIK 0001746251 · EVP & Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,395 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 19, 2020 and amended on December 7, 2020. Read SEC document |
| January 11, 2021 Filed Jan 13, 2021 21:08 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | Tax withholdingCommon Stock | 701 | $21.18 | $14,847.18 |
DisclosureSEC source: 0001192482-21-000058 · edgar.xml · nonDerivative · entry 1 Dreyer Scott · CIK 0001746251 · EVP & Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,717 F1 · shares: Shares withheld by the Issuer to satisfy applicable withholding taxes upon vesting of restricted stock units. Read SEC document |
| July 13, 2020 Filed Jul 14, 2020 20:06 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | SaleCommon Stock | 1,429 | $17.01 | $24,307.29 |
DisclosureSEC source: 0001192482-20-000621 · edgar.xml · nonDerivative · entry 2 Dreyer Scott · CIK 0001746251 · EVP & Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,418 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 22, 2019. Read SEC document |
| July 10, 2020 Filed Jul 14, 2020 20:06 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | Tax withholdingCommon Stock | 594 | $16.73 | $9,937.62 |
DisclosureSEC source: 0001192482-20-000621 · edgar.xml · nonDerivative · entry 1 Dreyer Scott · CIK 0001746251 · EVP & Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,847 F1 · shares: Shares withheld by the Issuer to satisfy applicable withholding taxes upon vesting of restricted stock units. Read SEC document |
| May 18, 2020 Filed May 20, 2020 20:18 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | Exercise / conversionStock Option (Right to Purchase) · Derivative | 8,000 | $0.00 Strike: $15.90 | $0.00 |
DisclosureSEC source: 0001192482-20-000350 · edgar.xml · derivative · entry 3 Dreyer Scott · CIK 0001746251 · EVP & Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,600 Underlying: Common Stock · 8,000 shares Expires 2029-01-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: 8,000 shares under the option are exercisable. The option, initially representing a right to purchase a total of 25,600 shares, vests and becomes exercisable over a four-year period. Twenty-five percent (25%) of the option vested and became exercisable on February 10, 2020, and the balance vests in equal quarterly installments (rounded up to the nearest whole share of common stock) over the following three-year period, subject to the reporting person's continued service with the issuer. Read SEC document |
| May 18, 2020 Filed May 20, 2020 20:18 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | SaleCommon Stock | 8,000 | $24.00 | $192,000.00 |
DisclosureSEC source: 0001192482-20-000350 · edgar.xml · nonDerivative · entry 2 Dreyer Scott · CIK 0001746251 · EVP & Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,441 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 7, 2019 and modified on March 5, 2020. Read SEC document |
| May 18, 2020 Filed May 20, 2020 20:18 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | Exercise / conversionCommon Stock | 8,000 | $15.90 | $127,200.00 |
DisclosureSEC source: 0001192482-20-000350 · edgar.xml · nonDerivative · entry 1 Dreyer Scott · CIK 0001746251 · EVP & Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,441 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 13, 2020 Filed May 15, 2020 20:15 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | SaleCommon Stock | 4,434 | $22.61 | $100,252.74 |
DisclosureSEC source: 0001192482-20-000346 · edgar.xml · nonDerivative · entry 1 Dreyer Scott · CIK 0001746251 · EVP & Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,441 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 7, 2019 and modified on March 5, 2020. Read SEC document |
| February 10, 2020 Filed Feb 12, 2020 21:27 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | Tax withholdingCommon Stock | 1,966 | $21.62 | $42,504.92 |
DisclosureSEC source: 0001192482-20-000150 · edgar.xml · nonDerivative · entry 1 Dreyer Scott · CIK 0001746251 · EVP & Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,875 F1 · shares: Shares withheld by the Issuer to satisfy applicable withholding taxes upon vesting of restricted stock units. Read SEC document |
| February 05, 2020 Filed Feb 7, 2020 21:10 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | GrantStock Option (Right to Purchase) · Derivative | 21,250 | $0.00 Strike: $21.34 | $0.00 |
DisclosureSEC source: 0001192482-20-000137 · edgar.xml · derivative · entry 2 Dreyer Scott · CIK 0001746251 · EVP & Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,250 Underlying: Common Stock · 21,250 shares Expires 2030-02-05 F2 · derivative.exercise_date: Twenty-five percent (25%) of the option vests and becomes exercisable on February 10, 2021, and the balance vests in equal quarterly installments (rounded up to the nearest whole share of common stock) over the following three-year period, subject to the reporting person's continued service with the issuer. Read SEC document |
| February 05, 2020 Filed Feb 7, 2020 21:10 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | GrantCommon Stock | 19,125 | $0.00 | $0.00 |
DisclosureSEC source: 0001192482-20-000137 · edgar.xml · nonDerivative · entry 1 Dreyer Scott · CIK 0001746251 · EVP & Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,841 F1 · security: Reflects the grant of restricted stock units. Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. Twenty-five percent (25%) of the restricted stock units vest on February 10, 2021, and the balance of the restricted stock units vest in equal annual installments over the following three-year period, subject to the reporting person's continued service with the issuer. The restricted stock units will be settled on each applicable vesting date in shares of the issuer's common stock. Read SEC document |
| January 14, 2020 Filed Jan 16, 2020 21:12 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | SaleCommon Stock | 1,321 | $23.87 | $31,532.27 |
DisclosureSEC source: 0001192482-20-000038 · edgar.xml · nonDerivative · entry 1 Dreyer Scott · CIK 0001746251 · EVP & Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,716 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 23, 2019. Read SEC document |
| January 10, 2020 Filed Jan 14, 2020 21:27 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | Tax withholdingCommon Stock | 702 | $23.30 | $16,356.60 |
DisclosureSEC source: 0001192482-20-000036 · edgar.xml · nonDerivative · entry 1 Dreyer Scott · CIK 0001746251 · EVP & Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,037 F1 · shares: Shares withheld by the Issuer to satisfy applicable withholding taxes upon vesting of restricted stock units. Read SEC document |
| July 11, 2019 Filed Jul 12, 2019 20:08 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | SaleCommon Stock | 2,857 | $12.31 | $35,169.67 |
DisclosureSEC source: 0001192482-19-000312 · edgar.xml · nonDerivative · entry 2 Dreyer Scott · CIK 0001746251 · EVP & Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,739 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 7, 2019. Read SEC document |
| July 10, 2019 Filed Jul 12, 2019 20:08 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | Tax withholdingCommon Stock | 1,190 | $12.44 | $14,803.60 |
DisclosureSEC source: 0001192482-19-000312 · edgar.xml · nonDerivative · entry 1 Dreyer Scott · CIK 0001746251 · EVP & Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,596 F1 · shares: Shares withheld by the Issuer to satisfy applicable withholding taxes upon vesting of restricted stock units. Read SEC document |
| January 25, 2019 Filed Jan 29, 2019 21:46 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | GrantStock Option (Right to Purchase) · Derivative | 25,600 | $0.00 Strike: $15.90 | $0.00 |
DisclosureSEC source: 0001192482-19-000061 · edgar.xml · derivative · entry 2 Dreyer Scott · CIK 0001746251 · EVP & Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,600 Underlying: Common Stock · 25,600 shares Expires 2029-01-25 F2 · derivative.exercise_date: Twenty-five percent (25%) of the option vests and becomes exercisable on February 10, 2020, and the balance vests in equal quarterly installments (rounded up to the nearest whole share of common stock) over the following three-year period, subject to the reporting person's continued service with the issuer. Read SEC document |
| January 25, 2019 Filed Jan 29, 2019 21:46 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | GrantCommon Stock | 25,600 | $0.00 | $0.00 |
DisclosureSEC source: 0001192482-19-000061 · edgar.xml · nonDerivative · entry 1 Dreyer Scott · CIK 0001746251 · EVP & Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,786 F1 · security: Reflects the grant of restricted stock units. Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. Twenty-five percent (25%) of the restricted stock units vest on February 10, 2020, and the balance of the restricted stock units vest in equal annual installments over the following three-year period, subject to the reporting person's continued service with the issuer. The restricted stock units will be settled on each applicable vesting date in shares of the issuer's common stock. Read SEC document |
| July 10, 2018 Filed Jul 12, 2018 20:41 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | GrantCommon Stock | 16,186 | $0.00 | $0.00 |
DisclosureSEC source: 0001192482-18-000337 · edgar.xml · nonDerivative · entry 1 Dreyer Scott · CIK 0001746251 · EVP & Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,186 F1 · security: Reflects the grant of restricted stock units in connection with the reporting person's promotion to Chief Commercial Officer of the issuer. Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. Twenty-five percent (25%) of the restricted stock units vest on July 10, 2019, and the balance of the restricted stock units vest in equal installments every six months (in each case, rounded up to the nearest whole share of common stock) over the following three-year period, subject to the reporting person's continued service with the issuer. The restricted stock units will be settled on each applicable vesting date in shares of the issuer's common stock. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.